フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
As filed with the U.S. Securities and Exchange Commission on June 2, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND EXCHANGE...
As filed with the U.S. Securities and Exchange Commission on May 9, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND EXCHANGE...
As filed with the U.S. Securities and Exchange Commission on April 22, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...
As filed with the U.S. Securities and Exchange Commission on April 14, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...
As filed with the U.S. Securities and Exchange Commission on April 6, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...
As filed with the U.S. Securities and Exchange Commission on March __, 2022 Registration No. 333-262878 UNITED STATESSECURITIES AND...
As filed with the U.S. Securities and Exchange Commission on February __, 2022 Registration No. [●] UNITED...
VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW...
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for...
o NoneEntity Type0001642178Breathtec BioMedical, Inc.Breathtec Biomedical, Inc. x Corporation o Limited Partnership o Limited...
Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory...
Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency...
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約